Predicting response to transdiagnostic iCBT for emotional disorders from patient and therapist involvement.
Emotional disorders
Guidance
Transdiagnostic
Usage
iCBT
Journal
Internet interventions
ISSN: 2214-7829
Titre abrégé: Internet Interv
Pays: Netherlands
ID NLM: 101631612
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
09
04
2021
revised:
16
06
2021
accepted:
18
06
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
Transdiagnostic iCBT has been shown to be effective for the treatment of emotional disorders. Less is known about the optimal level of therapist and patient involvement in these interventions. Specific characteristics of Internet-delivered interventions include treatment adherence (e.g., amount of review of the materials) and guidance (e.g., amount of therapist support). Exploring the importance of these elements in treatment outcome may help to maximize the efficiency of Internet-delivered psychological interventions. In this study, we aimed to analyze the relationship between patient and therapist involvement (i.e., platform usage and amount of therapist guidance) in a sample of patients with emotional disorders who received transdiagnostic iCBT in Spanish public specialized mental healthcare services. This is a secondary analysis of a randomized controlled trial. The sample included 63 patients who completed transdiagnostic iCBT for emotional disorders. Platform usage metrics included number of logins into the platform and number of times the participants reviewed the modules. Therapist guidance was measured as the number of support phone calls with a therapist and their total duration (minutes). Logistic regressions and ROC analyses were performed to explore the predictive value of platform usage and therapist guidance in symptom reduction. Clinical outcomes included depressive and anxiety symptoms assessed at baseline and post-intervention. The bivariate relationship between the platform usage and therapist guidance variables was also explored. Overall, platform usage and therapist guidance were not associated with symptom improvement. However, the patient and therapist involvement parameters were intercorrelated. Specifically, the number of calls and their duration were associated with a greater number of logins ( The results suggest that there is no reliable cut-off point for platform usage and therapist guidance in predicting optimal symptom reduction. However, significant associations were found between platform usage and guidance variables that warrant additional research. More research on this topic is necessary to further clarify the role of these and other platform usage and guidance variables in Internet-delivered iCBT outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Transdiagnostic iCBT has been shown to be effective for the treatment of emotional disorders. Less is known about the optimal level of therapist and patient involvement in these interventions. Specific characteristics of Internet-delivered interventions include treatment adherence (e.g., amount of review of the materials) and guidance (e.g., amount of therapist support). Exploring the importance of these elements in treatment outcome may help to maximize the efficiency of Internet-delivered psychological interventions.
AIM
OBJECTIVE
In this study, we aimed to analyze the relationship between patient and therapist involvement (i.e., platform usage and amount of therapist guidance) in a sample of patients with emotional disorders who received transdiagnostic iCBT in Spanish public specialized mental healthcare services.
METHOD
METHODS
This is a secondary analysis of a randomized controlled trial. The sample included 63 patients who completed transdiagnostic iCBT for emotional disorders. Platform usage metrics included number of logins into the platform and number of times the participants reviewed the modules. Therapist guidance was measured as the number of support phone calls with a therapist and their total duration (minutes). Logistic regressions and ROC analyses were performed to explore the predictive value of platform usage and therapist guidance in symptom reduction. Clinical outcomes included depressive and anxiety symptoms assessed at baseline and post-intervention. The bivariate relationship between the platform usage and therapist guidance variables was also explored.
RESULTS
RESULTS
Overall, platform usage and therapist guidance were not associated with symptom improvement. However, the patient and therapist involvement parameters were intercorrelated. Specifically, the number of calls and their duration were associated with a greater number of logins (
DISCUSSION
CONCLUSIONS
The results suggest that there is no reliable cut-off point for platform usage and therapist guidance in predicting optimal symptom reduction. However, significant associations were found between platform usage and guidance variables that warrant additional research. More research on this topic is necessary to further clarify the role of these and other platform usage and guidance variables in Internet-delivered iCBT outcomes.
Identifiants
pubmed: 34401379
doi: 10.1016/j.invent.2021.100420
pii: S2214-7829(21)00060-9
pmc: PMC8350608
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100420Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Med Internet Res. 2009 Apr 24;11(2):e13
pubmed: 19403466
Int J Environ Res Public Health. 2020 Aug 25;17(17):
pubmed: 32854381
J Med Internet Res. 2019 Aug 01;21(8):e12775
pubmed: 31373272
World Psychiatry. 2019 Feb;18(1):20-28
pubmed: 30600624
J Med Internet Res. 2013 Oct 17;15(10):e231
pubmed: 24135213
J Med Internet Res. 2018 Apr 19;20(4):e90
pubmed: 29674307
Internet Interv. 2019 Aug 15;18:100266
pubmed: 31890619
Psychiatr Serv. 2017 May 1;68(5):427-429
pubmed: 28412890
J Med Internet Res. 2016 Jun 17;18(6):e159
pubmed: 27317358
Depress Anxiety. 2014 Jun;31(6):506-16
pubmed: 24448889
Clin Psychol Rev. 2015 Aug;40:91-110
pubmed: 26094079
J Med Internet Res. 2020 Jul 7;22(7):e18220
pubmed: 32673226
J Med Internet Res. 2010 Nov 18;12(4):e52
pubmed: 21087922
Br J Health Psychol. 2010 Feb;15(Pt 1):1-39
pubmed: 19646331
Sci Rep. 2018 Feb 12;8(1):2861
pubmed: 29434331
J Affect Disord. 2016 Jul 15;199:30-41
pubmed: 27060430
J Anxiety Disord. 2018 Apr;55:70-78
pubmed: 29422409
Clin Psychol Rev. 2012 Jun;32(4):329-42
pubmed: 22466510
PLoS One. 2013 Nov 07;8(11):e79024
pubmed: 24244406
J Med Internet Res. 2006 Sep 29;8(3):e20; author reply e21
pubmed: 17032636
Harv Rev Psychiatry. 2017 May/Jun;25(3):114-122
pubmed: 28475503
Trials. 2015 Oct 31;16:488
pubmed: 26519046
JMIR Ment Health. 2016 Jun 14;3(2):e25
pubmed: 27302200
Neuropsychiatr Dis Treat. 2017 Mar 31;13:987-1006
pubmed: 28408833
Internet Interv. 2018 Apr 06;12:181-188
pubmed: 30135782
World Psychiatry. 2014 Feb;13(1):4-11
pubmed: 24497236
Internet Interv. 2017 Nov 17;11:1-10
pubmed: 30135754
J Med Internet Res. 2020 Mar 24;22(3):e15824
pubmed: 32207689
Emotion. 2020 Feb;20(1):30-36
pubmed: 31961174
J Med Internet Res. 2011 Aug 05;13(3):e52
pubmed: 21821503
J Med Internet Res. 2017 Dec 06;19(12):e402
pubmed: 29212630
J Affect Disord. 2018 Mar 15;229:443-449
pubmed: 29331706
Span J Psychol. 2008 Nov;11(2):626-40
pubmed: 18988448
PLoS One. 2014 Jul 16;9(7):e100674
pubmed: 25029507
Cogn Behav Ther. 2018 Jan;47(1):1-18
pubmed: 29215315
Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):291-7
pubmed: 20528315
J Consult Clin Psychol. 2008 Apr;76(2):341-6
pubmed: 18377129
Internet Interv. 2017 Sep 22;10:29-38
pubmed: 30135750